Biogen Idec Earnings Preview: Analysts Expect Higher EPS, Revenue
Biogen Idec (NASDAQ: BIIB) unveils its next round of earnings this Friday, October 28, 2011. Here's Benzinga's advanced look at Biogen Idec's third quarter earnings report.
Earnings and Revenue:
Ahead of the company's earnings announcement, analysts are expecting a positive EPS reading of $1.51/share and revenues of $1.27 billion. Biogen Idec's latest numbers will no doubt be compared with the company's year-ago quarter, when it reported a profit of $1.33/share on revenues of $1.18 billion. We'll have to wait for Friday to see if Biogen Idec has accomplished the estimated 13.5% rise in EPS and 7.6% increase in revenues on a year-over-year basis.
Here's how the company's reported EPS has stacked up against analyst estimates in the past:
| Quarter | Q2 | Q1 | Q4 | Q3 |
| EPS Estimate | $1.39 | $1.39 | $1.23 | $1.20 |
| EPS Actual | $1.35 | $1.42 | $1.41 | $1.33 |
Stock Performance:
As of October 24, 2011, Biogen Idec's current share price was $109.52. Since January 1st, shares of Biogen Idec have given investors a return of 63.3%. For a full 12 months, the return has risen by 65%. Given that these returns are generally positive, long-term shareholders are probably satisfied going into this earnings release.
- Long-term shareholders are already enjoying 12-month gains prior to the announcement
Average Stock Rating:
The average rating by analysts for Biogen Idec is a Moderate Buy. The strength of this rating has risen over the past three months.
Competitors:
Wondering how Biogen Idec compares to rivals in the same sector? Here are a few of the company's peers.
- Abbott Laboratories Com Stk NPV (NYSE: ABT): Hold with a $1.18 recent quarter EPS
- Amgen (NASDAQ: AMGN): Moderate Buy with a $1.35 recent quarter EPS
- Bristol-Myers Squibb (NYSE: BMY): Hold with a $0.56 recent quarter EPS
- ELAN CORPORATION PLC ADR (ELN): Hold with a -$0.02 recent quarter EPS
Biogen Idec is in the medical-bioengineering industry, which has experienced price/earnings growth of 0.3%.
Finally, a description of the company's main areas of operation: Biogen Idec is a global biotechnology company that meets the rising needs of therapeutic care providers and recipients.
Take Action:
Now that you're fully prepared, get ready to take quick action if the company reports any numbers significantly different from those listed above. Also, check back in with us after the announcement for a full recap and what-to-do-next guide.
- To see up-to-date news on Biogen Idec, click here
- To see other trading ideas, click here
- To see other company earnings recaps, click here
